H. Lee Moffitt Cancer Center and Research Institute
The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.5 months.
Inclusion Criteria: * Participants must have histologically or cytologically confirmed prostate cancer that has progressed to mCRPC with no grade 2 or above cancer related symptoms. * Participants need to have either PSA or imaging progression at castrate level of serum testosterone (i.e. \<50ng/dl). The definition of PSA progression and the definitions of imaging progression on measurable or non-measurable lesions will be based on the prostate cancer working group 3 (PCWG3) criteria. Patients with symptomatic oligo progression (1-3 sites), the symptoms need to be improved to grade 1 or less…
IM injection of Tc at 400 mg (Tc400) every 28 days for up to 3 doses.
Continuing ADT with either surgical castration or chemical castration with LHRH analog is considered standard of care for mCRPC.
IV at 7.4GBq (200mCi) once every 6 weeks for up to 6 doses.
Arctuva estimate
Verify or correct the compensation shown for this listing.